Natural Capsules Limited Announces COO Retirement and Rights Issue for Material Subsidiary

1 min read     Updated on 30 Sept 2025, 07:01 PM
scanx
Reviewed by
Suketu GalaScanX News Team
whatsapptwittershare
Overview

Natural Capsules Limited has announced two significant developments. First, the company's Chief Operating Officer, Mr. MVN Kutty, will retire due to superannuation, effective September 30, 2025. Second, the company's material subsidiary, Natural Biogenex Private Limited, has approved a rights issue of 11,11,200 equity shares at ₹10 per share, totaling ₹1,11,12,000.

20784684

*this image is generated using AI for illustrative purposes only.

Natural Capsules Limited , a prominent player in the pharmaceutical industry, has made two significant announcements that could impact its operational structure and financial position.

Retirement of Chief Operating Officer

Natural Capsules Limited has disclosed the retirement of Mr. MVN Kutty, the company's Chief Operating Officer (COO). According to the company's filing with the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), Mr. Kutty's retirement is due to superannuation and will be effective from the close of business hours on September 30, 2025.

The retirement announcement was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided the following details in its regulatory filing:

Particulars Details
Name Mr. MVN Kutty
Designation Chief Operating Officer
Reason for change Retirement on attaining superannuation
Date of cessation Close of business hours on September 30, 2025

Rights Issue for Material Subsidiary

In a separate announcement made on the same day, Natural Capsules Limited informed the stock exchanges about a significant development concerning its material subsidiary, Natural Biogenex Private Limited. The Board of Directors of Natural Biogenex Private Limited has approved a rights issue in their meeting held on September 30, 2025.

The key details of the rights issue are as follows:

Particulars Details
Number of Equity Shares 11,11,200
Face Value ₹10.00 each
Issue Price At par (₹10.00 per share)
Total Issue Size ₹1,11,12,000.00

This rights issue is expected to infuse additional capital into Natural Biogenex Private Limited, potentially strengthening its financial position and supporting its growth initiatives.

Both announcements were made by Pranjal Deshmukh, the Company Secretary & Compliance Officer of Natural Capsules Limited, in accordance with regulatory requirements. These developments may have implications for the company's operational strategy and financial outlook in the coming months.

Investors and stakeholders of Natural Capsules Limited are advised to take note of these announcements and assess their potential impact on the company's future performance.

Historical Stock Returns for Natural Capsules

1 Day5 Days1 Month6 Months1 Year5 Years
-0.75%+25.61%+38.47%+43.41%+9.02%+9.02%
Natural Capsules
View in Depthredirect
like19
dislike

Natural Capsules Limited Shareholders Approve Key Board Changes and Appointments at 32nd AGM

1 min read     Updated on 05 Aug 2025, 11:37 PM
scanx
Reviewed by
Radhika SahaniScanX News Team
whatsapptwittershare
Overview

Natural Capsules' 32nd AGM saw shareholders approve several important resolutions. Mr. Tekkar Yashwanth Prabhu will continue as Non-Executive Independent Director beyond 75 years. Mr. Sathyanarayana Mundra was reappointed as Whole Time Director for three years. Mr. R. Parthasarathy was appointed as Secretarial Auditor for five years. Other approvals included adoption of financial statements, reappointment of Mr. Sushil Kumar Mundra, related party transactions, and commission for Non-Executive Directors. All resolutions passed with overwhelming majority.

15962836

*this image is generated using AI for illustrative purposes only.

Natural Capsules , a leading manufacturer of hard capsule shells, held its 32nd Annual General Meeting (AGM) on August 4, 2025, where shareholders approved several significant resolutions shaping the company's governance and future direction.

Board Continuity and Reappointments

Shareholders gave their nod to the continuation of Mr. Tekkar Yashwanth Prabhu as a Non-Executive Independent Director beyond the age of 75 years until the expiry of his current term. Mr. Prabhu, with over four decades of banking experience, brings valuable expertise to the board, having served in senior positions at Canara Bank, Union Bank of India, and Oriental Bank of Commerce.

The meeting also saw the reappointment of Mr. Sathyanarayana Mundra as Whole Time Director for a three-year term, effective September 20, 2025, along with a revision in his remuneration. Mr. Mundra, responsible for quality control of products, will continue to play a crucial role in the company's operations.

New Appointments

In a move to strengthen its corporate governance, the company appointed Mr. R. Parthasarathy as Secretarial Auditor for a period of five consecutive years, from the financial year 2025-26 to 2029-30. Mr. Parthasarathy, a practicing Company Secretary with 38 years of experience in company law matters, brings extensive expertise to this role.

Other Key Resolutions

The AGM also addressed several other important matters:

  1. Adoption of audited financial statements for the year ended March 31, 2025.
  2. Reappointment of Mr. Sushil Kumar Mundra as a director, who was retiring by rotation.
  3. Approval of related party transactions with the subsidiary, Natural Biogenex Private Limited.
  4. Approval for the payment of commission to Non-Executive Directors.

Voting Results

All resolutions put forth at the AGM were passed with overwhelming majority. The e-voting results showed 100% votes in favor for most resolutions, indicating strong shareholder support for the company's decisions.

Management's Perspective

While specific comments from the management were not provided, the approval of these resolutions suggests a focus on maintaining experienced leadership, enhancing corporate governance, and preparing for future growth.

Natural Capsules, known for pioneering the manufacturing of vegetarian capsules in India, continues to evolve its governance structure to support its position as a key player in the pharmaceutical industry. These board-level changes and appointments are likely aimed at steering the company through its next phase of growth and expansion.

Historical Stock Returns for Natural Capsules

1 Day5 Days1 Month6 Months1 Year5 Years
-0.75%+25.61%+38.47%+43.41%+9.02%+9.02%
Natural Capsules
View in Depthredirect
like17
dislike
More News on Natural Capsules
Explore Other Articles
272.05
-2.05
(-0.75%)